Kissei

Rigel has agreements with Kissei to develop and commercialize TAVALISSE (fostamatinib disodium hexahydrate) and REZLIDHIA (olutasidenib) in Japan and other specified Asian countries.

TAVALISSE

  • Rigel has an exclusive license and supply agreement with Kissei to develop and commercialize TAVALISSE in all potential indications in Japan, China, Taiwan and the Republic of Korea.
  • TAVALISSE launched in Japan in April 2023 for the treatment of adult chronic immune thrombocytopenia (ITP).
  • In January 2025, Kissei announced that its licensing partner in South Korea, JW Pharmaceutical Corporation, had obtained marketing authorization for TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.
  • Rigel received an upfront cash payment, is eligible for regulatory and commercial milestone payments, and receives product transfer price payments based on tiered net sales of TAVALISSE in the territory.

REZLIDHIA

  • Kissei gained exclusive rights to develop and commercialize REZLIDHIA in all current and potential indications in Japan, Taiwan, and the Republic of Korea in September 2024.
  • Rigel received an upfront cash payment, and is eligible for development, regulatory and commercial milestone payments, and product transfer price payments based on tiered net sales of REZLIDHIA in the territory.